PUBLIC COMPANY
save$INCYINCYTE CORP
$INCY115.30-1.57%Wilmington, DE, USupdated 14h ago
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
community read0 votes
🐶 often sniffed alongside
top 5pipeline
11
marketed
4
phase 3
1
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(11)
pipeline depth11 products
2Phase 12Phase 21Phase 34Marketed1pre_registration1Unknown
Marketed
Opzelura
Hidradenitis Suppurativa
Tyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2
Marketedaxatilimab
Graft Versus Host Disease (GVHD)
Marketedpemigatinib
Metastatic Bile Duct Cancer
Fibroblast growth factor receptor 3Fibroblast growth factor receptor 1
Marketedretifanlimab
Squamous Non-Small Cell Lung Cancer
Programmed cell death protein 1
Phase 3tafasitamab
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associat…
B-lymphocyte antigen CD19
Phase 2ruxolitinib phosphate
Hemophagocytic Lymphohistiocytosis
Tyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2
Phase 2zilurgisertib fumarate
Fibrodysplasia Ossificans Progressiva (Myositis Ossifican…
Phase 1INCA-033989
Essential Thrombocythemia
Phase 1INCB-100658
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
drugZYNYZ
1 INDICATIONS AND USAGE ZYNYZ is a programmed death recep…
Programmed cell death protein 1
pre_registrationpovorcitinib phosphate
Hidradenitis Suppurativa
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase2INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
- phase3Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
- phase3Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- phase2A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- phase3A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- phase3A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- phase3A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
- phase1A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 17, 26SELLCAGNONI PABLO J· President, Global Head of R&D−$1.80M↗
routine RSU / option mechanics (6)
- Apr 17, 26option exerciseCAGNONI PABLO J · President, Global Head of R&D12,590 sh
- Apr 17, 26option exerciseCAGNONI PABLO J · President, Global Head of R&D6,077 sh
- Apr 17, 26option exerciseCAGNONI PABLO J · President, Global Head of R&D12,590 sh
- Apr 17, 26option exerciseCAGNONI PABLO J · President, Global Head of R&D6,077 sh
- Apr 15, 26option exerciseMeury William · Chief Executive Officer125,000 sh
- Apr 15, 26grantCAGNONI PABLO J · President, Global Head of R&D27,892 sh
🐶 Hiring Signal
next earnings Oct 27, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that